Boehringer Ingelheim gets CDSCO panel nod to market Jardiance for additional indication

Published On 2021-11-01T11:24:48+05:30 | Updated On 1 Nov 2021 5:54 AM GMT

Overview

In a significant development, drug-major Boehringer has got a go ahead from the Subject Expert Committee (SEC) of the Central Drugs Standard Control Organization (CDSCO) to market its popular diabetes drug empagliflozin for an additional indication to reduce the risk of cardiovascular death plus hospitalisation for heart failure in adults with heart failure and reduced ejection fraction in adults.

This nod came after the firm presented the USFDA approval details for Empagliflozin Tablets 10/25mg as a new indication to reduce the risk of cardiovascular death plus hospitalisation for heart failure in adults with heart failure and reduced ejection fraction, in light of the SEC recommendation dated 09.03.2021 and 10.03.2021.

For more details, check out the full story on the link below:

Boehringer Ingelheim Gets CDSCO Panel Nod To Market Jardiance For Additional Indication

Speakers

Roshni Dhar

Roshni Dhar, a Mass com graduate with a soft corner for health happenings, joined Medical Dialogues as a news anchor in 2021. Inspired by her mother who is a gynaecologist, she likes to keep herself and the world updated on the occurring in the medical field. She covers various aspects of health news for MDTV at Medical Dialogues. She can be reached at editorial@medicaldialogues.in.